Organ preservation following radiation therapy and concurrent intra-arterial low dose cisplatin infusion for advanced T2 and T3 laryngeal cancer: Long-term clinical results from a pilot study.
Background
This pilot study evaluated the long-term outcomes of patients with advanced T2 or T3 squamous cell carcinoma of the larynx (SCC-L) who were treated with selective intra-arterial cisplatin and concomitant radiotherapy (RADPLAT).


Methods
We retrospectively investigated the data of 49 patients with advanced T2 or T3 SCC-L who received a RADPLAT regimen with low-dose cisplatin.


Results
The 5-year locoregional control, disease-specific survival, and overall survival rates were 83.3%, 88.1%, and 82.6%, respectively, while the 5-year freedom from laryngectomy, laryngectomy-free survival, and laryngo-esophageal dysfunction-free survival rates were 89.6%, 79.4%, and 77.1%, respectively. The incidences of grade 3-4 hematologic and nonhematologic toxicities were 18% and 6%, respectively. Although two patients (4%) developed late toxicities within 5 years following RADPLAT, no other events were noted beyond 5 years.


Conclusion
This pilot study demonstrated that RADPLAT is feasible and safe and yielded favorable survival outcomes and functional laryngeal preservation in patients with advanced T2 or T3 SCC-L.


Level of evidence
3.
['Ono|Takeharu|T|https://orcid.org/0000-0003-2414-7034', 'Tanaka|Norimitsu|N|', 'Tanoue|Syuichi|S|', 'Miyata|Yusaku|Y|', 'Muraki|Koichiro|K|', 'Tsuji|Chiyoko|C|', 'Ogo|Etsuyo|E|', 'Aso|Takeichiro|T|', 'Chitose|Shun-Ichi|SI|https://orcid.org/0000-0002-9307-2331', 'Shin|Buichiro|B|', 'Kakuma|Tatsuyuki|T|', 'Etoh|Hidehiro|H|', 'Hattori|Chikayuki|C|', 'Abe|Toshi|T|', 'Umeno|Hirohito|H|']
radiation therapy squamous cell carcinoma late toxicity laryngeal preservation concurrent intra‐arterial low dose cisplatin infusion